EP Patent

EP4007602A1 — A dosing regimen for an ido inhibitor

Assigned to Incyte Corp · Expires 2022-06-08 · 4y expired

What this patent protects

The present disclosure relates to dosing regimens for treating cancer by administering epacadostat in combination with an antibody, or an antibody fragment thereof, that binds to PD-1.

USPTO Abstract

The present disclosure relates to dosing regimens for treating cancer by administering epacadostat in combination with an antibody, or an antibody fragment thereof, that binds to PD-1.

Drugs covered by this patent

Patent Metadata

Patent number
EP4007602A1
Jurisdiction
EP
Classification
—
Expires
2022-06-08
Drug substance claim
No
Drug product claim
No
Assignee
Incyte Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.